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Abstract 
Rad18 functions at the cross-roads of three different DNA damage response (DDR) 
pathways involved in protecting stressed replication forks: homologous 
recombination repair, DNA inter-strand cross-link repair and DNA damage tolerance. 
Whilst Rad18 serves to facilitate replication of damaged genomes by promoting 
translesion synthesis (TLS), this comes at a cost of potentially error-prone lesion 
bypass. In contrast, loss of Rad18-dependent TLS potentiates the collapse of stalled 
forks and leads to incomplete genome replication. Given the pivotal nature with which 
Rad18 governs the fine balance between replication fidelity and genome stability, 
Rad18 levels and activity have a major impact on genomic integrity. Here, we identify 
the de-ubiquitylating enzyme USP7 as a critical regulator of Rad18 protein levels. 
Loss of USP7 destabilises Rad18 and compromises UV-induced PCNA mono-
ubiquitylation and Pol η recruitment to stalled replication forks. USP7-depleted cells 
also fail to elongate nascent daughter strand DNA following UV-irradiation and show 
reduced DNA damage tolerance. We demonstrate that USP7 associates with Rad18 
directly via a consensus USP7-binding motif and can disassemble Rad18-dependent 
poly-ubiquitin chains both in vitro and in vivo. Taken together, these observations 
identify USP7 as a novel component of the cellular DDR involved in preserving 
genome stability. 
  
3 
 
Introduction 
The ability to recognize and accurately repair damaged DNA is essential for 
viability. In addition to repair processes that actively remove DNA lesions, cells have 
evolved mechanisms for tolerating the presence of damaged DNA that interferes with 
DNA replication. DNA damage tolerance (DDT) mechanisms are important for 
maintaining ongoing replication of genomes containing unrepaired bulky DNA lesions 
that block conventional replicative DNA polymerases and disrupt replication fork 
progression.  
It is becoming clear that post-translational modifications and especially 
ubiquitylation/de-ubiquitylation play a major role in both DNA repair as well as the 
regulation of DNA damage tolerance during replication (1). For example, bulky DNA 
lesions e.g. UV-induced cyclobutane pyrimidine dimers that block replicative DNA 
polymerases and thus stall replication forks, can activate the E3 ubiquitin ligase 
Rad18, which together with its E2-conjugating enzyme Rad6, catalyzes the mono-
ubiquitylation of PCNA on lysine K164 (2-4). This modification of PCNA facilitates the 
binding of specialized translesion synthesis (TLS) DNA polymerases, which can 
efficiently synthesize past bulky DNA adducts (5-8). However, Rad18-mediated 
lesion bypass is inherently error-prone and must be used sparingly in order to avoid 
mutations. Rad18-deficient cells are TLS-compromised and hypo-mutagenic (9-11) 
while ectopically over-expressed Rad18 results in DNA damage-independent PCNA 
mono-ubiquitylation and recruitment of TLS polymerases to replication forks (12, 13). 
Therefore, appropriate control of Rad18 expression levels is important for balancing 
replication stress tolerance with mutagenesis. 
In addition to regulating protein-protein interactions, ubiquitylation can also 
alter the stability, localization or functionality of a protein. In this respect, whereas the 
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mono-ubiquitylation of PCNA increases its interaction with TLS polymerases, the 
same modification on DNA polymerase eta renders the protein inactive by blocking 
both its nuclear localization signal and its ability to bind PCNA (6). Similarly, the 
mono-ubiquitylation of Rad18 has also been proposed to negatively regulate the 
DNA damage tolerance pathway, through its ability to block its interaction with HLTF 
and SHPRH (14); two E3 ubiquitin ligases required to carry out error-free bypass of a 
DNA lesion. Moreover, in contrast to unmodified Rad18, which resides in the 
nucleus, the mono-ubiquitylated form of Rad18 has been shown to be predominantly 
localized to the cytoplasm (15), suggesting that this modification may suppress 
Rad18 activity via multiple different mechanisms. 
Removal of ubiquitin from mono- and poly-ubiquitylated proteins is also critical 
for determining the ubiquitylation state of various E3 ligase substrates. Increasingly, it 
is becoming clear that de-ubiquitylating (DUB) enzymes play major roles in 
controlling a wide variety of different cellular processes including the response to 
DNA damage (16). One DUB that has received a lot of attention, primarily through its 
well-documented role in controlling the stability of the p53-directed E3 ubiquitin 
ligases MDM2 and MDMX, is the Herpes associated ubiquitin specific protease, 
USP7/Hausp. In unstressed cells, USP7 binds to and stabilizes MDM2/MDMX, which 
in turn promotes the poly-ubiquitylation of p53 and its subsequent destruction by the 
proteasome (17). Upon induction of DNA damage, the interaction between USP7 and 
MDM2/MDMX is disrupted (18) by ATM-dependent phosphorylation (19), which 
functions to promote the ubiquitin-dependent destruction of MDM2/MDMX, thus 
allowing p53 to accumulate. Originally identified through its association with the 
Herpes Simplex Virus E3 ligase ICP0, USP7 has been found to regulate the stability 
of a multitude of different cellular proteins many of which are E3 ubiquitin ligases, 
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including CHFR and more recently, UHRF1 and HLTF (20-23). In addition to 
controlling protein stability, USP7 has also been reported to affect both the cellular 
compartmentalization and activity of a number of its substrates (24).  
Here, we identify Rad18 as a novel USP7 binding partner and substrate.  
USP7-mediated de-ubiquitylation protects Rad18 from proteasomal degradation and 
is necessary for the integrity of the TLS pathway. Importantly, USP7-deficiency 
recapitulates key phenotypes of TLS-deficient cells including defective replication of 
damaged genomes and UV hypersensitivity. Owing to its key roles in multiple DNA 
damage signaling pathways, USP7 may allow coordination of Rad18-mediated TLS 
with other branches of the DDR including p53 signaling, Chk1 and Rad5-mediated 
PRR. Moreover, since Rad18 confers tolerance to chemotherapeutic agents such as 
cisplatin and camptothecin, our results suggest a rationale for the use of USP7 
inhibitors as chemo-sensitizers to treat tumours clinically. 
 
Results 
USP7 depletion leads to destabilization of Rad18 protein levels 
Given that Rad18 has been shown to undergo poly-ubiquitylation and 
proteasome-mediated degradation in vivo (15), we hypothesised that this poly-
ubiquitylation-coupled Rad18 degradation maybe counteracted by a Rad18-targeted 
de-ubiquitylating activity. To test this hypothesis, we used siRNA to individually 
deplete a subset of DUBs, previously identified to function in the DNA damage 
response (16), to determine what impact loss of these DUBs has on the stability of 
Rad18. Strikingly, we observed that compromising USP7 levels but not those of 
USP1, USP11, USP3 or USP28, resulted in a significant reduction in the levels of 
Rad18 (Figure 1A). Importantly, the reduction in Rad18 levels was not due to siRNA 
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‘off-target’ effects as we obtained similar results using multiple USP7-directed 
siRNAs (Figure 1B). Moreover, USP7-/- HCT116 cells expressed reduced levels of 
Rad18 when compared with the parental (USP7-expressing) HCT116 cells. In 
addition, pharmacological inhibition of USP7 using HBX19818 also recapitulated the 
effect of USP7-deficiency on Rad18 expression (Figure 1C). Critically, this reduction 
of Rad18 protein levels in USP7-deficient cells could not be accounted for by any 
alterations in either Rad18 mRNA expression or cell cycle distribution 
(Supplementary Figure 1A and 1B).  
Treatment with the proteasome inhibitor MG132 partially rescued the reduced 
Rad18 protein levels resulting from either siRNA-mediated USP7-depletion (Figure 
1D), pharmacological inhibition of USP7 activity (Figure 1E left panel), or inactivation 
of the USP7 gene (Figure 1E right panel). Combined, these results indicate that 
Rad18 is actively degraded by the proteasome in response to loss of USP7 DUB 
activity. Crucially, re-expression of a siRNA-resistant WT but not a catalytically-
inactive ('Dead') mutant USP7 in cells lacking endogenous USP7, substantially 
restored Rad18 levels demonstrating that the enzymatic activity of USP7 is 
necessary for maintaining normal Rad18 protein expression (Figure 1F). Taken 
together, these data demonstrate that USP7 is important for maintaining cellular 
pools of Rad18 and that upon loss of this protection Rad18 is targeted for 
proteasomal degradation.  
 
Cells lacking USP7 exhibit defects in the DNA damage tolerance pathway. 
 Given that loss of USP7 function led to substantial reduction in Rad18 protein 
levels, we asked whether USP7-depletion would recapitulate hallmarks of Rad18-
deficiency. First, we tested the effect of USP7-depletion on DNA damage-induced 
7 
 
mono-ubiquitylation of PCNA, the best-characterized substrate of Rad18. Strikingly, 
USP7 deficient cells displayed a significant reduction in the levels of UV-induced 
PCNA mono-ubiquitylation (mUb-PCNA) when compared to cells expressing USP7 
(Figure 2A and Supplementary Figure 2). 
One critical function of PCNA mono-ubiquitylation is to provide a docking site 
for TLS polymerases (3, 5, 7, 8, 25, 26), for example DNA Pol η, which binds to 
mUb-PCNA through its PIP motif, ubiquitin-binding domain (UBZ) and PCNA 
interacting region (PIR) (3, 6, 7). As shown in Fig. 2B, the UV-induced redistribution 
of Pol η to sites of replication fork stalling (determined by the quantification of cells 
with nuclear GFP-Pol η foci) was reduced by 40-60% in USP7-depleted cells relative 
to control siRNA transfected cells. Importantly, this was not due to an alteration in the 
levels of Pol η because they remained unaffected by USP7 depletion in multiple cell 
lines (Supplementary Figure 3).   
Due to an inability of replication forks to bypass bulky DNA lesions, DNA 
damage bypass deficient cells, such as those lacking Rad18, Polη or Rev1, exhibit 
defective elongation of nascent DNA strands following UV-treatment, termed a post-
replication repair (PRR) defect (10, 27, 28). To ascertain whether USP7 knockdown 
would give rise to deficiency in PRR, we used alkaline sucrose gradient 
sedimentation centrifugation to determine the effects of USP7-depletion on the 
elongation rates of newly-replicated DNA in UV-irradiated cells. Notably, the DNA 
size-distribution profiles in Fig. 2C show that USP7-depleted cells accumulated high 
molecular mass DNA at a reduced rate compared to control cells. More importantly, 
this effect was similar but not as severe to that observed in Rad18 deficient cells 
(Supplementary Figure 4) Therefore, USP7-deficiency leads to decreased chain 
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elongation following UV-treatment, recapitulating a major phenotype of Rad18/TLS-
deficient cells. 
USP7 has also been shown to control the stability of HLTF (Supplementary 
Figure 5A and (23)), which has recently been implicated in potentiating the levels of 
PCNA mono-ubiquitylation in response to replication stress (29).  Therefore, we 
considered the possibility that HLTF dysregulation may contribute to the TLS-related 
phenotype we observed in USP7 defective cells. However, despite HLTF expression 
being knockdown to almost undetectable levels, this had no impact on the levels of 
UV-induced PCNA mono-ubiquitylation, indicating that reduced HLTF levels in USP7-
depleted cells do not account for the attenuation of PCNA mono-ubiquitylation 
(Supplementary Figure 5B). 
It has been shown that a deficiency in Rad18, Rev1 or DNA Polζ-dependent 
TLS gives rise to a hypo-mutagenic phenotype following UV irradiation (9-11, 30-35) 
whereas HLTF depletion renders cells hyper-mutagenic (29), Therefore, we 
determined the effect of USP7-depletion on mutagenesis using a plasmid-based 
reporter assay (29). As shown in Fig. 2D, USP7-depletion had no effect on 
spontaneous mutagenesis of an undamaged reporter plasmid. Strikingly, however, 
the mutation frequency of UV-damaged reporter plasmids was reduced by 
approximately 50% in USP7-deficient cells when compared to control cells (Figure 
2D). This observation is in agreement with the hypo-mutagenic phenotype of 
Rad18/TLS deficient cells following UV-irradiation (9-11, 30-35) and further indicates 
that reduced HLTF levels do not account for the PRR defects we observed in cells 
lacking USP7. Furthermore, consistent with the phenotypes of Rad18/TLS-deficient 
cells, USP7-depletion conferred a modest hypersensitivity to agents that induce 
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replication stress (including UV, MMC, and HU) but not IR, which induces DSBs 
(Figure 2E).   
To directly ascertain if a reduction in Rad18 expression is the underlying 
cause for the sub-optimal UV-induced mono-ubiquitylation of PCNA in USP7 
depleted cells, we used an inducible cell system to allow for the controlled re-
expression of Rad18 in USP7 siRNA transfected cells. HeLa cells expressing a 
doxycycline-inducible WT Flag-tagged Rad18 expression construct were transfected 
with USP7 siRNA and 72 hours following transfection, doxycycline was added to the 
media for 24 hours. The cells were then UV irradiated, harvested six hours post-
irradiation and extracts analyzed by Western blotting (Figure 2F). As expected, in the 
absence of doxycycline, we found that cells depleted of USP7 exhibited a reduction 
in levels of PCNA mono-ubiquitylation (compare lane 7 with lane 3). However, this 
was restored upon re-expression of Rad18 following the addition of doxycycline 
(compare lane 8 with lane 4). This observation is consistent with the premise that 
dysregulation of Rad18 levels accounts for the reduced PCNA mono-ubiquitylation in 
USP7 depleted cells.  
Taken together, our results demonstrate that USP7 confers Rad18 stability, 
and is necessary for Rad18 effector functions in response to the induction of 
genotoxic stress including Pol η redistribution to sites of UV lesions, replication of 
damaged genomes, mutagenesis and DNA damage tolerance. 
 
USP7 associates with Rad18 and dismantles Rad18-dependent poly-ubiquitin 
chains in vitro and in vivo. 
Since USP7 is implicated in regulating the stability of a number of different 
substrates, including several E3 ubiquitin ligases, we wished to examine whether the 
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requirement for USP7 to maintain Rad18 levels was direct or mediated by a USP7-
dependent pathway. To determine whether Rad18 and USP7 exist in a complex, we 
performed reciprocal immunoprecipitations to isolate ectopically co-expressed, 
epitope-tagged forms of Rad18 and WT or catalytically-inactive (Dead) USP7 from 
HEK293 cell extracts. Notably, we observed a robust interaction between Rad18 and 
USP7 that was enhanced when the enzymatic activity of USP7 was ablated (Figure 
3A). Moreover, purified, recombinant forms of Rad18 and USP7 could also bind 
together in vitro (Figure 3B) indicative that this interaction is direct. 
Given that USP7 and Rad18 associate and that Rad18 auto-ubiquitylation has 
been proposed to target it for proteasomal degradation (15), we reasoned that the 
dependence of Rad18 stability on USP7 could be a mediated through its ability to 
antagonize Rad18 auto-ubiquitylation. To address this, Rad18-dependent auto-
ubiquitylation reactions were carried out in the presence or absence of recombinant 
purified WT and catalytically inactive USP7. Strikingly, the robust auto-ubiquitylation 
of Rad18, detected with either an anti-Rad18 or anti-poly-ubiquitin (FK2) antibody 
was completely abolished by the addition of WT but not DUB-dead USP7 (Figure 
3C), strongly indicating that USP7 is capable of antagonising the E3 ubiquitin ligase 
activity of Rad18 in vitro. Moreover, the specificity of USP7 activity was verified by 
the observation that the addition of recombinant USP25 (an irrelevant DUB) to the 
Rad18 auto-ubiquitylation reaction failed to reverse Rad18-dependent ubiquitin chain 
formation (Supplementary Figure 6). 
To ascertain whether Rad18 poly-ubiquitin chains are also targeted by USP7 
in vivo, MRC5 cells were transfected with either WT ubiquitin or a mutant ubiquitin 
harboring a lysine-48 to arginine substitution (designated 'K48R', which cannot form 
poly-ubiquitin chains), together with either a WT or DUB Dead USP7 mammalian 
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expression construct. The cells were then treated with MG132 to promote 
stabilization of poly-ubiquitin chains and a Rad18 antibody was used to detect 
endogenous poly-ubiquitylated Rad18. As shown in Figure 3D, endogenous Rad18 
was modified by K48-linked poly-ubiquitin chains in vivo (compare lanes 3 with 5) 
that was suppressed by the over-expression of WT USP7 (compare lanes 3 with 6) 
but not by the catalytically-inactive USP7 mutant (compare lanes 6 with 7). These 
results indicate that USP7 is a novel Rad18-directed DUB that removes K48-linked 
poly-ubiquitin chains generated via Rad18 auto-ubiquitylation. 
 
Rad18 has a consensus USP7 binding motif required to maintain its stability in 
vivo. 
To map the region of Rad18 responsible for mediating its binding to USP7, a 
panel of overlapping Rad18 fragments fused to GST was incubated with recombinant 
full length USP7, co-associated proteins were purified on glutathione beads and 
detected using Western blotting (Figure 4A). Interestingly, these binding studies 
identified amino acids 110-251 of Rad18 (which encompass the Ubiquitin-Binding 
Zinc motif) as the USP7-binding domain (Figure 4A).  
Notably, the region of Rad18 we identified as being necessary for its 
interaction with USP7 using in vitro binding assays (amino acids 110-251) contained 
two motifs conforming to the consensus USP7 binding sequence previously identified 
in other USP7 interacting proteins (P/AxxS: where position +1 is either a proline or 
alanine, x is any amino acid and position +4 is a serine, which has been shown to be 
critical for USP7 binding) (36). To ascertain if either of these binding motifs mediates 
the interaction with USP7, we mutated the consensus serine residues at amino acids 
183 or 192/194 of Rad18 to alanine and then repeated the in vitro binding assays 
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with the two mutant Rad18 fragments (Figure 4B). Whereas mutation of the serine at 
position 183 on Rad18 had no effect on its interaction with USP7 in vitro, mutation of 
the two serines at position 192 and 194 in the second PxxS motif completely 
abolished USP7-binding (Figure 4B). Co-immunoprecipitation analysis using extracts 
from 239T cells co-expressing full length USP7 and either WT Rad18 or a 
S192/194A Rad18 mutant confirmed that the serine residues 192 and 194 in the 
Rad18 protein are also essential for binding to USP7 in vivo (Figure 4C).  
 More importantly, in keeping with a role for this PxxS motif in modulating the 
stability of Rad18, analysis of in vivo protein half-life using cycloheximide in MRC5 
cells revealed that the S192/194A mutant Rad18 is profoundly less stable than its 
WT counterpart (Figure 4D). Furthermore, the accelerated degradation of this mutant 
Rad18 was completely abrogated in cells that were previously transfected with USP7 
siRNA, indicating that the S192/194A mutation in Rad18 renders it more unstable 
than the WT protein only in the presence of USP7 (Figure 4E). To ascertain the 
impact of this mutation on Rad18-dependent functions in response to UV-irradiation, 
MRC5 cells were first transfected with Rad18 siRNA and 48 hours later were further 
transfected with either an siRNA-resistant WT or S192/194A HA-tagged RAD18 
expression construct or an empty vector. The cells were then UV irradiated and the 
levels of PCNA mono-ubiquitylation or GFP-Pol η re-localisation were determined by 
Western blotting (Figure 4F) and immunofluorescence microscopy respectively 
(Figure 4F). Interestingly, we noted that the S192/194A mutant HA-Rad18, when 
transiently expressed at similar levels to the WT protein, could efficiently promote 
both the UV-induced mono-ubiquitylation of PCNA and also the relocalisation of 
GFP-Pol η to sites of damage. Therefore, we can conclude that the S192/194A 
Rad18 mutation does not adversely impact Rad18 function directly. However, a 
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failure to bind USP7 renders the Rad18 S192/194A unstable and as a consequence, 
compromises its ability to effectively promote both PCNA mono-ubiquitylation and Pol 
η relocalisation to sites of UV stalled replication.  
 
 
Discussion 
 In our study, we identify a novel role for USP7 in regulating an important 
effector branch of the response to DNA damage, namely TLS. In particular, we 
demonstrate that the primary mechanism by which USP7 controls this pathway in 
response to replication damage is by regulating the stability of Rad18; the principal 
E3 ubiquitin ligase that directs activation of the DNA damage tolerance pathway 
through its ability to mono-ubiquitylate PCNA. Intracellular Rad18 levels can have a 
major influence on the activation state of the TLS pathway: reduced Rad18 
expression attenuates PCNA mono-ubiquitylation and as a result compromises 
replication of damaged genomes. Consequently, this can lead to fork collapse, DSB 
formation and ultimately, cell death (37). In addition, Rad18-deficiency also renders 
cells hypo-mutagenic (owing to reduced activation of error-prone Y-family 
polymerases (9-11). Conversely, aberrant high-level expression of Rad18 can 
promote PCNA mono-ubiquitylation and drive recruitment of Y-family TLS 
polymerases to replication forks even in the absence of DNA damage (12, 13). This 
could potentially increase mutation rates and potentiate cellular transformation. 
Therefore, it is clear that Rad18 expression levels can have a major influence on 
DNA damage tolerance, mutagenesis and the maintenance of genomic stability. 
A recent report by Qian et al. suggested that another component of the TLS 
pathway, Pol η, is a direct target of USP7-mediated de-ubiquitylation (38). This study 
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shows that the DUB activity of USP7 promotes the degradation of Pol η by stabilising 
MDM2, which has been previously reported to poly-ubiquitylate Pol η (39). 
Furthermore, the authors report that ectopic USP7 over-expression, can lead to 
increased Pol η stability, which they suggest promotes the mono-ubiquitylation of 
PCNA following UV irradiation in these cells. Our analysis demonstrates that USP7 
depleted cells display reduced levels of Rad18 and as a result, defective PCNA 
mono-ubiquitylation and Pol η re-localisation following UV-irradiation. In contrast to 
the observation by Qian et al. that USP7 loss increases Pol η stability, we have not 
detected any alterations either in Pol η protein levels or Pol η protein turnover in cells 
lacking USP7 (Supplementary Figures 3 A-D). However, even if Pol η stability is 
increased upon USP7 loss, based on our data, it would still not relocalise efficiently 
to sites of stalled replication in these cells (Figure 2B). Moreover, the restoration of 
PCNA mono-ubiquitylation in USP7 deficient cells by the re-expression of Rad18 
(Figure 2F), further indicates that it is unlikely that the changes in PCNA mono-
ubiquitylation levels are due to increased Pol η stability. 
Although Rad18 function has been studied extensively, surprisingly little is 
known about how its expression levels are regulated. Our work underlines the 
importance of USP7 for Rad18 stability and as such for efficient DNA damage 
bypass. We have identified a consensus USP7 binding motif in Rad18 that protects 
the protein from accelerated degradation. Yamaizumi and colleagues demonstrated 
that Rad18 can poly-ubiquitylate itself and that this modified form of Rad18 can be 
targeted for degradation by the proteasome (15). Our study identifies USP7 as a 
novel Rad18-directed DUB that removes poly-ubiquitin chains and antagonizes the 
proteasomal degradation of Rad18. However, whether the poly-ubiquitin-directed 
degradation of Rad18 is driven solely by its auto-ubiquitylation, remains unclear. 
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Unfortunately, due to the inherent instability of catalytically-inactive Rad18 RING 
domain mutants (40) we have been unable to ascertain whether Rad18 poly-
ubiquitylation can occur independently of its catalytic activity. Moreover, we cannot 
rule out the involvement of other, as yet unidentified E3 ligases, contributing to the 
poly-ubiquitylation and subsequent degradation of Rad18.  
In addition to poly-ubiquitylation, Rad18 is also mono-ubiquitylated in 
mammalian cells. Interestingly, in many of our experiments it appeared that the 
unmodified form of Rad18 is more susceptible to degradation in the absence of 
USP7 than the mono-ubiquitylated form. It is tempting to speculate that the mono-
ubiquitylation of Rad18 makes it more resistant to poly-ubiquitylation and 
proteasomal-dependent degradation. In support of this, it has been shown that the 
mono-ubiquitylated form of Rad18 is almost exclusively localised in the cytoplasm 
(15) whereas in contrast, USP7 is primarily localised in the nucleus (41). As such, 
this could provide one explanation for the differential sensitivity of the unmodified 
versus mono-ubiquitylated forms of Rad18 to loss of USP7. Intriguingly, we also 
observed that even when USP7 is completely absent, the levels of Rad18 protein are 
never completely depleted. Whilst the underlying reason for this is unknown, this is 
consistent with a specific pool of Rad18, perhaps the mono-ubiquitylated form, being 
somehow protected from degradation and as such does not require the de-
ubiquitylating activity of USP7. Moreover, since it is known that Rad18 exists as a 
dimer, it is possible that the unmodified Rad18 remaining in cells lacking USP7 is 
safeguarded from degradation through its association with a mono-ubiquitylated 
molecule of Rad18. In keeping with this, we repeatedly observed that the ratio of 
unmodified to mono-ubiquitylated forms in USP7 deficient cells shifted from a 
predomination of the unmodified form to stoichiometric amounts of both forms. 
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Recently, it has been suggested that the ubiquitylated form of Rad18 is 
inactive (14). It was proposed that the mono-ubiquitylation of Rad18 is required to 
mediate its dimerisation with another (unmodified) molecule of Rad18 resulting in its 
inactivation. However, following the induction of replication damage, the Rad18 dimer 
becomes de-ubiquitylated and subsequently activated. This observation highlights 
the point that regulating Rad18 ubiquitylation also plays a key role in controlling its 
activity. Currently, it is not clear whether USP7 contributes to the DNA damage-
inducible removal of the mono-Ub from the inactive Rad18 homo-dimer, although at 
least in vitro, USP7 is capable of completely de-ubiquitylating Rad18. Interestingly, 
when we over-expressed USP7 super-physiological levels in cells, rather than 
increasing the stability of Rad18, we observed a reduction in the mono-ubiquitylated 
form of Rad18. It is therefore possible that the elevated level of UV-induced PCNA 
mono-ubiquitylation in cells over-expressing USP7 reported by Qian et al. is 
mediated through the de-ubiquitylation and activation of Rad18. 
Since we have shown that USP7 is essential for maintaining Rad18 stability in 
cells and that loss of USP7 phenocopies the hallmark DDT defects associated with 
Rad18 deficiency, one inference from our work is that compromising USP7 function 
would be sufficiently detrimental to genomic integrity that it could potentiate cellular 
transformation. Interestingly, it has been recently demonstrated that a significant 
proportion of paediatric T cell acute lymphoblastic leukaemia (ALL) tumour samples 
have acquired somatic, loss-of-function mutations in USP7 (42). Since ablating USP7 
function results in p53 stabilisation and an increase in p53-dependent G1 arrest 
and/or apoptosis, it is somewhat difficult to rationalize how these mutations would be 
beneficial for tumourigenesis unless they are acquired in tumour cells that already 
have an inactivated the p53 pathway. However, it is tempting to speculate that 
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compromised Rad18-dependent DNA damage tolerance in USP7-defective tumour 
cells could permit the accumulation of DNA DSBs induced by replication stress, 
which if repaired inappropriately by non-homologous end-joining pathways, would 
give rise to the formation of gross genomic rearrangements; a process known to be 
necessary for transformation and/or disease progression. 
Despite that USP7 has been shown to be important for regulating the stability 
of a number of different cellular proteins, its link to the p53 pathway has been the 
principal driver for the development of inhibitors to be used as anti-cancer 
treatments. However, since inhibiting USP7 primarily induces p53-dependent cell 
death, it is plausible that the frequent inactivation of TP53 would allow tumour cells to 
resist cell death following USP7 loss. In spite of this, our data suggests that USP7 
inhibition could nevertheless sensitise tumours, (including those lacking functional 
p53), to genotoxic therapeutic agents such as cisplatin (43) or camptothecin (44) that 
are normally tolerated by cancer cells via Rad18-dependent mechanisms. As a 
consequence this work suggests that the potential therapeutic use of USP7 inhibitors 
could be widened to include those tumours with a defective p53 pathway, especially 
if combined with conventional chemotherapeutic agents. 
  
18 
 
Materials and Methods 
Cell culture 
HeLa, U2OS, 293T cells (ATCC) and 293FT (Invitrogen) were maintained in 
DMEM (Gibco, Invitrogen) supplemented with 10% foetal calf serum (FCS), 
glutamine and penicillin/streptomycin (pen/strep) at 37°C in 5% CO2. USP7 WT and 
knockout HCT116 cells were maintained in RPMI1640 (Gibco, Invitrogen) 
supplemented with 10% foetal calf serum (FCS), glutamine and 
penicillin/streptomycin (pen/strep) at 37°C in 5% CO2. MRC5-SV40 cells were 
maintained in MEM supplemented with 10% foetal calf serum (FCS) and glutamine. 
Flp-In/T-rex HeLa cells were a kind gift from Dr. Jakob Nilsson and maintained in 
DMEM supplemented with 10% FCS, glutamine, 200µg/ml hygromycin and 5µg/ml 
blasticidin. XP30RO (XP-Variant) or XP30R0 stably expressing POLH cDNA 
[XP30ROpolη] (45) were a kind gift from Dr. Patricia Kannouche and were maintained 
in MEM supplemented with 10% foetal calf serum (FCS) and glutamine. 
 
Chemicals/Inhibitors 
Doxycycline (used at 200ng/ml) was purchased from Sigma. Cycloheximide 
used at used at 60µg/ml was purchased from Merck Millipore. The USP7 inhibitor 
HBX19818 was kindly provided by Dr. Frédéric Colland (Hybrigenics) and has been 
previously reported elsewhere (46, 47). 
 
Plasmids 
The GFP- and Flag-tagged USP7 expression constructs were obtained from 
Dr. Madelon Maurice and have been previously described elsewhere (19). The 
pEGFP- and Flag-Rad18 expression constructs were a kind gift from Drs. Akira 
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Yasui, Jun Huang and Junjie Chen and have been previously published (48, 49). The 
plasmids encoding overlapping fragments of Rad18 fused to GST have been 
previously described (50). Introduction of the S192/194A mutation in the RAD18 ORF 
was achieved using the site-directed mutagenesis kit (Stratagene) according to the 
manufacturer’s instructions using the following primers Forward: CGT CCT GAG 
CCA CCC GCG ACA GCC ACT TTG AAA CAA GTT ACT and Reverse: AGT AAC 
TTG TTT CAA AGT GGC TGT CGC GGG TGG CTC AGG ACG. For the introduction 
of the S183A mutation the primers used were: Forward: AA GAG ATC GCT CCA 
GAT CCC GCA GAG GCT AAG, Reverse: CTT AGC CTC TGC GCG ATC TGG 
AGC GAT CTC TT. Expression constructs for GFP-pol η and HA-tagged wt Rad18 
were kindly provided by Dr. Patricia Kannouche.  
 
Antibodies and Western Blotting 
The anti-USP7, SMC1, Rad18, Rad6, HLTF, USP1, USP11, USP3 and 
USP28 antibodies were all purchased from Bethyl. The histone H2A (acidic patch) 
antibodies were obtained from Millipore. Antibodies to PCNA, cyclin A, Cdt1 and 
Rad51 were obtained from Santa-Cruz. The anti-Rad18, anti-Polη and β-Tubulin 
antibodies were all purchased from Abcam and the anti-poly-ubiquitin (FK2) antibody 
was obtained from Biomol. The anti-Flag (M2), β-actin and anti-HA epitope tag 
antibodies were purchased from Sigma. The anti-GFP (living colours) antibody was 
obtained from Clontech.  
 
siRNA and transfections 
The siRNA duplexes were all 21 base pairs with a 2-base deoxynucleotide 
overhang. The sequence of the custom USP7 and control siRNA oligonucleotides 
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used were: CCCAAATTATTCCGCGGCAAAdTdT and 
CGUACGCGGAAUACUUCGAdTdT respectively (Thermo Fisher). The Claspin, 
HLTF, USP1, USP3, USP11, USP28, DNA polymerase η (Polη) and USP7 
(AAGCGUCCCUUUAGCAUUAUU, GCAUAGUGAUAAACCUGUAUU, 
UAAGGACCCUGCAAAUUAUUU, and GUAAAGAAGUAGACUAUCGUU) siRNA on-
target plus SMARTpools and human RAD18 individual on-target plus oligonucleotide 
(GAAAUGAGUGGUUCUACAU) were all purchased from Thermo Fisher. Cells were 
transfected with siRNA duplexes using Oligofectamine (Invitrogen), following the 
manufacturer’s instructions. Cells were routinely harvested 72h after siRNA 
transfection. HeLa cells were transfected with a siRNA resistant Flag-USP7 
expression construct using Lipofectamine 2000 according to the manufacturer’s 
instructions.  
 
Immunofluorescence 
Following siRNA and pEGFP-Pol η transfections, HeLa or MRC5 cells were 
seeded onto coverslips and mock-irradiated or UV-irradiated. Cells were washed 
twice in PBS, fixed in 3.6% paraformaldehyde at room temperature for 20 min and 
were then sealed with vectashield containing DAPI (Vectorlabs). All slides were 
analyzed by fluorescence microscopy at x60 magnification (Nikon E600). 
 
Colony survival. 
Cells transfected with siRNA were seeded at low density and exposed to a 
variety of DNA damaging agents. Cells were left for 14 days at 37°C to allow colonies 
to form. Colonies were stained with 2% methylene blue/50% ethanol and counted. 
Colonies were defined as containing 50 or more cells. 
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Post-replication repair assay. 
The assay was performed as previously described with minor modifications 
(6). 
 
Mutagenesis assay. 
293T cells were transfected with non-target control or USP7-directed siRNAs 
using Lipofectamine 2000. 24 h later, the cells were transfected with an undamaged 
or UV-irradiated pSP189 reporter plasmid (Parris and Seidman, 1992) using 
Lipofectamine 2000. After 48 h, the pSP189 plasmid was recovered from the 293T 
cells using a DNA miniprep kit (QIAGEN). Purified plasmid DNA was DpnI-digested 
and electroporated into the MBM7070 bacterial strain. The mutation frequency in the 
SupF coding region was determined by enumerating the ratios of blue (wild-type) and 
white (mutant) colonies.  
 
Immunoprecipitation 
293FT cells transfected with epitope tagged USP7 and Rad18 expression 
constructs were lysed for 30 minutes in NETN lysis buffer (50mM Tris/HCl pH 7.5, 
150mM NaCl, 1mM EDTA, 2mM MgCl2, 1% NP40 supplemented with protease 
inhibitors (Roche) and Benzonase (Novagen). The clarified extract was pre-cleared 
with the appropriate IgG (Dako) and protein A or G beads (GE Healthcare) for 1 h at 
4˚C. Immuno-precipitating antibody (10 µg) was added to the pre-cleared 
supernatant for 2.5 hours followed by protein A or G beads and incubated for 1.5h at 
4˚C. The immuno-complexes were washed four times in NETN lysis buffer 
(containing 0.5% NP40), boiled in SDS sample buffer and loaded on an SDS–
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polyacrylamide gel. Proteins were analyzed by Western blotting using standard 
methods and detected with the antibodies described above. 
 
In vitro protein binding assay 
All reactions were conducted at 4°C unless otherwise stated. 
Immunoprecipitations using purified proteins were carried out as follows: 500ng of 
purified USP7 (BostonBiochem) and Rad18 (ORIGENE) were mixed for 2 hours at 
4˚C in a 500µl reaction with NETN buffer (50mM Tris pH 7.5, 1mM EDTA, 150mM 
NaCl and 0.5% NP-40) supplemented with a complete protease inhibitor cocktail 
(Roche). After this incubation, the reactions were span down at 44,000 rpm for 15 
min at 4˚C and the supernatants were incubated with 0.5µg of USP7 or Rad18 
(Bethyl) or rabbit IgG (DAKO) polyclonal antibodies in separate reactions overnight. 
The following day, the reactions were span down at 13,000 rpm for 5 min and the 
supernatants were mixed with 20µl of protein A beads and left on a carousel for 2 
hours. The reactions were span down at 3,000 rpm for 2min and the supernatants 
discarded. The beads were washed three times in 1ml NETN buffer (once in NETN 
with 150mM NaCl followed by two washes in NETN with 400mM NaCl) and were 
then re-suspended in 40µl SDS sample buffer and boiled for 5min at 95˚C. 
 
GST-pulldowns 
All reactions were carried out at 4°C unless otherwise stated. Equal amounts 
of GST-Rad18 protein fragments were mixed each with 500ng of purified His-tagged 
USP7 (Caltag Medsystems) in 500µl of NETN buffer (50mM Tris pH 7.5, 1mM EDTA, 
150mM NaCl and 1% NP-40) supplemented with complete protease inhibitor cocktail 
tablets (Roche) for 1 hour and were then span down at 13,000rpm for a min. The 
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supernatants were incubated for 1 hour with 20µl of GST-beads (per reaction) 
previously washed in the same buffer. After this incubation, the reactions were span 
down at 3,000 rpm for 2min and the supernatants discarded. The beads were then 
washed five times in 1ml NETN buffer and were then re-suspended in 40µl SDS 
sample buffer and boiled for 5min at 95˚C. 
 
In vitro ubiquitylation/de-ubiquitylation assays. 
0.2µg of E1, 0.5µg of E2 (Rad6), 0.5µg of the E3 (Rad18) and 5µg of ubiquitin 
were all mixed in a ubiquitylation reaction buffer containing 50mM Tris pH7.5, 5mM 
MgCl2, 1mM DTT and 1xATP regeneration buffer (Enzo Life Sciences) in a final 
volume of 20µl for 3 hours at 37°C. For de-ubiquitylation assays, after the 3 hour 
ubiquitylation reaction, increasing amounts (0.5µg, 1µg, 1.5µg) of purified USP7 
(Caltag Medsystems) or 0.5µg of recombinant WT or catalytically inactive (C223S) 
USP7 (A generous gift from Chris Boutell and Roger Everett) or WT USP25 (Enzo 
Life Sciences) were added to the mix (final volume of 30µl) and the reactions were 
further incubated for 2 hours at 37°C. In all cases reactions were terminated by the 
addition of SDS loading buffer and boiling for 10 min at 95°C.  
 
Flow cytometry  
PI analysis: Cells were stained with propidium iodide (PI) as previously 
described (51) and were analyzed by flow cytometry on an Accuri C6 flow cytometer 
(BD Biosciences) using the manufacturer’s software. 
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Quantitative RT-PCR (Q-PCR) 
RNA was extracted using RNeasy kit (Qiagen, Hilden, Germany) and 
complementary DNA was generated using Superscript II reverse transcriptase (Life 
Technologies). SYBR Green quantitative Real-time PCR (Life Technologies) was 
applied with primers against RAD18 (Fw: 5’- GCTTCTGGTGGATCAGGCTA-3’, Rev: 
5’- TCAGGTTCCAATTCCTCTGG-3’). Primers against β-ACTIN (Fw: 5’- 
CACCATTGGCAATGAGCGGTTC, Rev: 5’-AGGTCTTTGCGGATGTCCACGT-3’) 
were used for normalisation and quantification was achieved using the comparative 
Ct method (52).  
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FIGURE LEGENDS 
Figure 1 Rad18 protein levels are reduced in USP7 deficient cells and can be 
restored by proteasomal inhibition. A HeLa cells were transfected with control 
siRNA or siRNA against USP7, USP1, USP28, USP3 or USP11. The cells were 
harvested and extracts from these cells were subjected to Western blotting using the 
antibodies indicated. B HeLa cells were transfected with control siRNA, a single 
siRNA sequence targeting USP7 or a SMARTpool of USP7 siRNA sequences. The 
cells were harvested and extracts from these cells were subjected to Western blotting 
using the antibodies indicated. The loading control is a non-specific band recognized 
by the anti-Rad18 antibody. C HeLa cells were incubated with increasing amounts of 
a specific USP7 inhibitor (HBX19818) for 24 hours and the levels of USP7 and 
Rad18 monitored by Western blotting (left panel). The loading control is a non-
specific band recognized by Rad18 antibodies. The expression of Rad18 and USP7 
was determined by Western blotting on extracts derived from HCT116 cells either 
expressing USP7 (WT USP7) or in which USP7 had been knocked out (USP7-/-) 
(right panel). SMC1 was used as a loading control. D MRC5 cells were transfected 
with a single siRNA sequence targeting USP7 as in part ‘B’ and then incubated with 
MG132 for the indicated times. Extracts from these cells were subjected to SDS-
Page and Western blotting with the antibodies indicated. E MRC5 cells were 
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incubated with 15μM of the USP7 inhibitor (HBX19818) for 16 or 24 hours in the 
presence or absence of 10μM MG132. The levels of USP7, Rad18 and H2A were 
monitored by Western blotting (left panel). USP7-/- cells were incubated in media 
containing either DMSO or MG132 and the levels of Rad18 determined by Western 
blotting (right panel). Rad51 and Rad6 were used as loading controls. F HeLa cells 
were transfected with control or USP7 siRNA in conjunction with an empty vector, 
Flag-tagged WT USP7 or a catalytically dead USP7 mammalian expression 
construct. Extracts from these cells were subjected SDS-Page and Western blotting 
with the antibodies indicated.  
 
Figure 2 USP7 depleted cells fail to activate DNA damage tolerance following 
UV and phenocopy Rad18 deficient cells. A MRC5 cells were transfected with 
control or USP7 siRNA, UV-irradiated with 20J/m2 and then harvested at the times 
indicated. Extracts from these cells were subjected to SDS-Page and Western 
blotting with the indicated antibodies. B MRC5 cells stably expressing EGPF-Polη 
were transfected with control or USP7 targeted siRNA in conjunction with a plasmid 
encoding pEGFP-Polη. The cells were mock-irradiated or UV-irradiated with 15J/m2 
and the number of cells with Polη foci was determined. Representative microscopy 
images are depicted (top) together with quantification of the percentage of EGFP 
positive cells with Polη foci (bottom). C HeLa cells transfected with control or USP7 
siRNA were pulse-labeled with 3H-Thymidine, mock-treated or UV-irradiated, and 
then genomic DNA was extracted. 3H-Thymidine was measured using scintillation 
counter on fractions obtained from differential sucrose sedimentation centrifugation of 
the genomic DNA (gDNA). The blue and red curves denote the size of gDNA 
fragments obtained from UV irradiated cells transfected with either control or USP7 
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siRNA respectively. The inset graph represents an estimation of the average DNA 
molecular weight across the distribution normalized to the control siRNA.  D The 
mutation frequency was assessed 48 hrs after cotransfection of 293T cells with 
mock-treated or UV-irradiated plasmid (pSP189) and the indicated siRNAs. The data 
represent average +/- SEM (shown as error bar) from at least three independent 
experiments. E HeLa cells were transfected with control siRNA or siRNA against 
USP7 and were then exposed to ionizing radiation (IR), hydroxyurea (HU), mitomycin 
C (MMC) or ultraviolet radiation (UV) at the doses indicated. The cells were then left 
for 14 days at 37°C to allow colonies to form. Colonies were defined as containing 50 
or more cells. F HeLa Flp-In/T-Rex cells expressing Flag-tagged WT RAD18 were 
transfected with USP7 siRNA, incubated with doxycycline to promote induction of 
Rad18 expression and then either mock-irradiated or UV-irradiated with 30J/m2 and 
the levels of USP7, Rad18 and PCNA were monitored with the indicated antibodies. 
The asterisk denotes a non-specific band. 
 
Figure 3 USP7 associates with and deubiquitylates Rad18 in vitro and in vivo. 
A 293FT cells were transfected with plasmids encoding EGFP-RAD18 and either 
wild-type (WT) or catalytically inactive (C223S) (DEAD) Flag-USP7. USP7 or Rad18 
were immunoprecipitated from cell extracts using the indicated antibodies. The 
immuno-precipitated material was subjected to SDS-Page/Western blotting and the 
co-associated proteins detected with the indicated antibodies. B Purified Flag-tagged 
USP7 was incubated with purified Rad18 and immunoprecipitations were carried out 
using antibodies to either USP7 or Rad18. The immuno-precipitated material was 
subjected to SDS-Page/Western blotting and the co-associated proteins detected 
with the indicated antibodies. C Combinations of an E1 enzyme, an E2 enzyme 
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(Rad6), Rad18 and ubiquitin were mixed and incubated for 3 hours at 37°C. For de-
ubiquitylation assays, after the 3 hour ubiquitylation reaction, either recombinant WT 
or recombinant catalytically inactive (C223S) USP7 were added to the mix and the 
reactions were further incubated for 2 hours at 37°C. In all cases the reactions were 
terminated by the addition of Laemli buffer and boiling for 10 min at 95°C. The 
proteins were detected using the indicated antibodies. D MRC5 cells were 
transfected with plasmids encoding either WT or K48R ubiquitin (lanes 3-7), in some 
cases with Flag-tagged RAD18 (lanes 2 and 4) and either WT or catalytically inactive 
Flag-tagged USP7 (lanes 6 and 7 respectively) and then incubated in MG132. 
Extracts from these cells were blotted for Rad18, Flag-USP7 and β-Tubulin. 
Normalised differences (fold change) in Rad18-poly-ubiquitylation intensity between 
samples were analysed by densitometry and are depicted in red.  
 
Figure 4 A consensus USP7 binding motif in Rad18 is important for its stability. 
A Purified GST-tagged fragments of Rad18 were mixed with purified Flag-tagged 
USP7 and GST-pulldowns were performed as described in Materials and Methods. A 
schematic of the Rad18 fragments utilized is depicted (right panel). B GST pull-
downs were performed as in part ‘A’ but this time with a WT Rad18 fragment D or a 
mutant fragment D in which either S183 or S192/194 had been mutated to alanine 
(mutations denoted with X). The levels of co-precipitated USP7 were determined by 
Western Blotting. USP7 binding motifs identified in proteins known to interact with 
USP7 are shown. A comparison with two putative USP7 binding motifs identified in 
Rad18 is also shown. C 293FT cells were treated as in Figure 3A, except that cells 
were transfected with full length HA-tagged Rad18 (WT) or a mutant HA-tagged 
Rad18 where the serines S192 and 194 had been mutated to alanine and EGFP-
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USP7. HA-tagged Rad18 was immunoprecipitated from cell extracts using anti-HA 
antibodies and the immuno-precipitated material was subjected to SDS-
Page/Western blotting and the co-associated proteins detected with the indicated 
antibodies. D MRC5 cells were transfected with an empty vector (v) or a construct 
expressing either WT HA-tagged Rad18 or the S192/194A mutant HA-tagged Rad18. 
The cells were then incubated in media containing cycloheximide at a concentration 
of 60µg/ml for the indicated periods. Extracts from these cells were fractionated by 
SDS-Page and the levels of Rad18 determined by Western blotting. β-Actin was 
used as a loading control. E MRC5 cells were treated as in part ‘D’ with the exception 
that prior to DNA transfection endogenous USP7 was knocked down with siRNA. 
Quantification by densitometry of normalised HA-Rad18 protein levels in each 
sample is depicted in the graphs below Figures 4D and 4E, respectively.  F MRC5 
cells were transfected with a single Rad18 siRNA sequence for 48hrs and then with a 
siRNA-resistant WT or S192/194A HA-tagged Rad18 construct only (left panel). 
24hrs following transfection the cells were UV irradiated as indicated and 6hours later 
they were harvested. Extracts from the harvested cells were fractionated by SDS-
Page and HA-Rad18 expression and PCNA monoubiquitylation was monitored by 
Western blotting. (left panel). These cells were additionally transfected with pEGPF-
Pol η (right panel), fixed 6 hours after UV-irradiation and EGFP-Pol η localization 
was analyzed by fluorescence microscopy (right panel). At least 300 cells were 
analysed per condition.  
 
Supplementary Figures 
Supplementary Figure 1 siRNA mediated knockdown of USP7 does not affect 
cell cycle progression or the expression of Rad18. A HeLa cells were transfected 
33 
 
with the indicated siRNA sequences and 48 or 72 hours later the cells were fixed with 
ethanol, stained with PI and subjected to Flow cytometry analysis. B Hela cells were 
transfected with control, USP7 or Rad18 siRNA and 48 or 72 hours later the cells 
were harvested and cDNA generated from the extracted RNA. Rad18 mRNA was 
quantified using quantitative PCR (qPCR) and is represented as a percentage 
expression relative to control siRNA transfected cells following normalisation to β-
actin mRNA. 
 
Supplementary Figure 2 USP7 deficient cells display reduced levels of 
hydroxyurea-induced PCNA mono-ubiquitylation. A MRC5 cells were transfected 
with control or USP7 siRNA and 48hrs following siRNA transfection they were 
exposed to 1mM HU for 24 hours. Extracts from these cells were subjected to SDS-
Page and the levels of USP7, Rad18 and PCNA mono-ubiquitylation were 
determined.  
 
Supplementary Figure 3 USP7 depletion does not alter Pol η protein levels.  A 
MRC5 cells were transfected with control or USP7 siRNA, UV irradiated with 20J/m2 
and then harvested at the indicated times. The levels of both USP7 and DNA Pol η 
were monitored by Western blotting. B 293T cells were transfected with control or 
USP7 siRNA, 72 hours later were harvested and the levels of USP7, Rad18 and 
DNA Pol η were analysed by Western blotting. The asterisk denotes a non-specific 
band. C MRC5 (lane 1) or XP30RO (XP-Variant) (lane 2) and XP30RO-Pol η 
complemented cells (lane 3) were all harvested and the levels of Pol η, TopBP1 and 
β-Tubulin were monitored by Western blotting using the indicated antibodies. The 
asterisk denotes a non-specific band. D MRC5 cells were transfected as in A and 72 
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hrs later they were incubated in media containing cycloheximide at a concentration of 
(100µg/ml) for the indicated periods. The efficiency of USP7 knockdown and protein 
half-life rates in the presence of cycloheximide were analysed using the indicated 
antibodies. The asterisk denotes a non-specific band.  
 
Supplementary Figure 4 USP7 depletion gives rise to a PRR defect comparable 
to loss of Rad18 
HeLa cells transfected with control, USP7 or Rad18 targeted siRNA were pulse-
labeled with 3H-Thymidine, UV-irradiated, and then genomic DNA was extracted. 3H-
Thymidine was measured using scintillation counter on fractions obtained from 
differential sucrose sedimentation centrifugation of the gDNA. The inset graph 
represents an estimation of the average DNA molecular weight across the 
distribution normalized to the control siRNA. 
 
Supplementary Figure 5 HLTF depletion does not affect the induction or the 
levels of PCNA mono-ubiquitylation following UV irradiation. A Hela cells were 
transfected with USP7 siRNA and 72 hours following transfections the levels of both 
USP7 and HLTF were analysed by Western blotting. The asterisk denotes a non-
specific band. B MRC5 cells were transfected with control or HLTF specific siRNA, 
irradiated with 20J/m2 of UV and then harvested at various times post-irradiation. The 
efficiency of HTLF knockdown, Rad18 levels and the ubiquitylation of PCNA were all 
determined by Western blotting.  
 
Supplementary Figure 6 Rad18 is specifically de-ubiquitylated in vitro by USP7 
but not USP25. In vitro ubiquitylation reactions using E1, Rad6, Rad18 and ubiquitin 
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were carried out as in Figure 3C. For the de-ubiquitylation assays, after the 3 hour 
ubiquitylation reaction, recombinant USP7 or USP25 was added to the mixture and 
the reactions were incubated for a further 2 hours at 37°C. The reactions were 
terminated by the addition of Laemli buffer and boiling. The proteins were detected 
using the indicated antibodies. 
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